What immediate‑release diltiazem dose regimen is equivalent to a 120 mg once‑daily extended‑release (non‑XR) tablet?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Diltiazem 120mg Extended-Release Conversion to Immediate-Release

For a patient taking 120mg once-daily extended-release diltiazem, convert to immediate-release diltiazem 30mg four times daily (total 120mg/day) to maintain equivalent total daily dosing. 1

Conversion Rationale

The American College of Cardiology guidelines specify that immediate-release diltiazem is dosed at 30-90mg four times daily, while extended-release formulations are dosed at 120-360mg once daily. 1 The key principle is maintaining the same total daily dose when converting between formulations. 2

Practical Dosing Schedule

  • Immediate-release: 30mg four times daily (e.g., 8 AM, 12 PM, 4 PM, 8 PM) provides equivalent 24-hour coverage to 120mg extended-release once daily. 1
  • Alternatively, 40mg three times daily (total 120mg/day) may be used if four-times-daily dosing is impractical, though this is less ideal for maintaining consistent blood levels. 1

Important Pharmacokinetic Differences

  • Immediate-release diltiazem has a half-life of 4.5-12 hours, requiring multiple daily doses to maintain therapeutic levels, whereas extended-release formulations provide consistent 24-hour drug delivery. 3
  • The extended-release formulation maintains steady plasma concentrations above the therapeutic threshold (≥40 ng/mL) throughout the dosing interval, while immediate-release requires frequent dosing to avoid trough periods. 4

Clinical Considerations for Conversion

When This Conversion Is Appropriate

  • Patients unable to swallow extended-release capsules (which cannot be split or crushed) may require immediate-release tablets. 5
  • Hospitalized patients requiring more flexible dosing or those transitioning to intravenous therapy may benefit from immediate-release formulations. 1

Monitoring After Conversion

  • Reassess blood pressure and heart rate within 1 week after converting to immediate-release to ensure adequate control throughout the 24-hour period. 3
  • Watch for breakthrough symptoms (elevated blood pressure, angina, or rapid heart rate) particularly in the hours before the next immediate-release dose. 3

Critical Safety Warnings

Absolute Contraindications Apply to Both Formulations

  • Do not use diltiazem in any formulation in patients with second- or third-degree AV block without a functioning pacemaker, sick sinus syndrome without a pacemaker, decompensated systolic heart failure, severe left ventricular dysfunction, cardiogenic shock, or Wolff-Parkinson-White syndrome with atrial fibrillation/flutter. 1, 3

Drug Interaction Alerts

  • Diltiazem is both a CYP3A4 substrate and moderate CYP3A4 inhibitor—exercise caution with apixaban, rivaroxaban, simvastatin (maximum 10mg daily), cyclosporine, and other CYP3A4 substrates. 3
  • Avoid concurrent beta-blocker therapy due to increased risk of profound AV block, symptomatic bradycardia, and heart failure. 1, 3

Common Pitfall to Avoid

Do not assume 120mg once-daily extended-release can be replaced with 120mg once-daily immediate-release—immediate-release diltiazem dosed once daily will not provide adequate 24-hour coverage due to its shorter half-life, resulting in loss of therapeutic effect during trough periods. 1, 3 The immediate-release formulation requires division into multiple daily doses (typically four times daily) to match the pharmacokinetic profile of extended-release. 1

References

3
Guideline

Diltiazem Dosing and Management for Hypertension and Angina

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

5
Guideline

Tapering Diltiazem CD 120mg

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

What is the protocol for switching from diltiazem ER to Cartia XT?
Is a dose of diltiazem 240 mg twice daily appropriate?
When switching from daily extended-release (ER) Cardizem (diltiazem) 120mg to twice-daily, should extended-release (ER) formulation still be used?
Can diltiazem extended‑release (ER) 60 mg be administered twice daily (BID) for a 12‑hour formulation?
What are the target blood pressure parameters for a patient on Cardizem (diltiazem)?
What is the recommended intrathecal (spinal) dose of hyperbaric bupivacaine 0.5% for a healthy adult undergoing lower‑abdominal, urologic, orthopedic, or lower‑extremity surgery?
What are the appropriate doses, contraindications, precautions, and common adverse effects of Promethazine DM (promethazine and dextromethorphan) for treating cough in adults and children aged 6–12 years?
In a patient with chronic heart failure who presents with hypernatremia (serum sodium ≈150 mEq/L) and hypovolemia (hypotension, orthostatic changes, dry mucous membranes, reduced skin turgor, weight loss, low central venous pressure), how should the hypernatremia be managed?
What evidence supports trying an antidepressant at its minimum effective dose for at least four to six weeks before concluding it is ineffective?
What is the appropriate ivermectin dosing regimen (200 µg/kg oral dose repeated after one week) for scabies in adults and children ≥15 kg on chronic hemodialysis and for their close contacts?
How can I safely switch a patient taking alprazolam 0.5 mg three times daily (total 1.5 mg per day) to a longer‑acting benzodiazepine and taper the regimen?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.